Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Loxo Oncology CS (LOXO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,287,365
  • Shares Outstanding, K 26,150
  • Annual Sales, $ 0 K
  • Annual Income, $ -72,400 K
  • 36-Month Beta 2.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.48

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.52 +13.67%
on 03/31/17
49.95 -7.79%
on 04/27/17
+1.72 (+3.88%)
since 03/28/17
3-Month
37.87 +21.63%
on 01/30/17
49.95 -7.79%
on 04/27/17
+7.55 (+19.61%)
since 01/27/17
52-Week
17.14 +168.73%
on 11/03/16
49.95 -7.79%
on 04/27/17
+22.56 (+96.00%)
since 04/28/16

Most Recent Stories

More News
Loxo Oncology Announces Proof of Concept Clinical Data for Larotrectinib in TRK Fusion Glioblastoma Presented at the AACR Annual Meeting 2017

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that larotrectinib...

LOXO : 46.06 (-6.44%)
Loxo Oncology Announces Larotrectinib Pan-TRK IHC Companion Diagnostic Collaboration with Ventana Medical Systems, Inc., a member of the Roche Group

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the Company has...

MDSY : 0.70 (-4.11%)
LOXO : 46.06 (-6.44%)
After Valeant, Here are 5 Drug Stocks Bill Ackman Should Buy Instead

With Bill Ackman finally deciding to exit Valeant (VRX), here is a look at 5 Zacks Rank #1 and #2 drug stocks that the billionaire investor could consider buying.

CNCE : 15.87 (-0.75%)
NDRM : 28.88 (+0.28%)
BCRX : 6.34 (-1.09%)
LOXO : 46.06 (-6.44%)
VRX : 9.25 (-1.39%)
NEOS : 7.10 (-4.70%)
Loxo Oncology Reports Fourth Quarter and Year-End 2016 Financial Results

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today reported fourth quarter and...

LOXO : 46.06 (-6.44%)
Should You Sell Loxo Oncology (LOXO) Before Earnings?

Investors are always looking for stocks that are poised to beat at earnings season and Loxo Oncology, Inc. (LOXO) may be one such company.

LOXO : 46.06 (-6.44%)
Loxo Oncology to Present at Cowen and Company 37th Annual Health Care Conference

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that Joshua H. Bilenker,...

LOXO : 46.06 (-6.44%)
Loxo Oncology Announces Completion of Clinical Trial Enrollment for Larotrectinib NDA Primary Efficacy Analysis

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the company has...

LOXO : 46.06 (-6.44%)
Loxo Oncology Announces the Closing of its Follow-On Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced the closing of its...

MS : 43.37 (-0.39%)
LOXO : 46.06 (-6.44%)
Loxo Oncology (LOXO) Surges: Stock Moves 25.8% Higher

Loxo Oncology, Inc. (LOXO) moved big last session, as its shares jumped almost 26% on the day.

SCMP : 10.15 (+0.50%)
LOXO : 46.06 (-6.44%)
Loxo Oncology TRK Inhibitor Larotrectinib (LOXO-101) Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in ESMO Asia Phase 1 Update

- Six of Seven TRK Fusion Patients Achieve Confirmed RECIST Partial Responses and All Remain in Response -

LOXO : 46.06 (-6.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut.

See More

Support & Resistance

2nd Resistance Point 51.24
1st Resistance Point 48.65
Last Price 46.06
1st Support Level 44.54
2nd Support Level 43.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.